|1.||Sasano, Hironobu: 21 articles (11/2015 - 04/2005)|
|2.||Seckl, Jonathan R: 18 articles (12/2015 - 11/2006)|
|3.||Walker, Brian R: 17 articles (12/2015 - 02/2004)|
|4.||Griendling, Kathy K: 17 articles (01/2014 - 01/2002)|
|5.||Shah, Ajay M: 14 articles (12/2015 - 10/2002)|
|6.||Savchenko, A A: 14 articles (10/2014 - 08/2001)|
|7.||Drummond, Grant R: 14 articles (09/2014 - 12/2008)|
|8.||Wilson, William R: 13 articles (01/2015 - 09/2007)|
|9.||Sobey, Christopher G: 13 articles (09/2014 - 12/2008)|
|10.||Malech, Harry L: 12 articles (04/2015 - 12/2002)|
|1.||Cardiovascular Diseases (Cardiovascular Disease)
08/01/2013 - "However, data from experimental and animal studies strongly support that dysregulated redox signaling, resulting from hyperactivation of various cellular oxidases or mitochondrial dysfunction, is integral to the pathogenesis and progression of cardiovascular disease (CVD). "
12/01/2013 - "We also summarize the benefits of exercise training in tackling the hyperactivation of cellular oxidases and mitochondrial dysfunction seen in cardiovascular diseases. "
06/01/2012 - "3-hydroxy-3-methylglutaryl-coenzymeA reductase inhibitors, or statins, represent an important class of agents that improve clinical outcomes in atherosclerotic cardiovascular disease. "
01/01/2011 - "Hexose-6 phosphate dehydrogenase (H6PDH) is a microsomal enzyme whose activity regulates corticosteroid metabolism in the liver and adipose tissue; variability in measures of corticosteroid metabolism within the normal range have been associated with risk factors for cardiovascular disease. "
11/01/2005 - "Inhibitors of 3-hydroxy-3-methylglutaryl coenzymeA reductase are widely used in the management and prevention of cardiovascular disease. "
02/20/2012 - "We have reported that hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), which are used for treatment of hypercholesterolemia, activate PPARγ and mediate anti-atherogenic effects through PPARγ activation in macrophages. "
09/01/1996 - "A reductase inhibitor, over 26 weeks in patients with primary hypercholesterolemia. "
12/25/1987 - "3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia."
03/01/1985 - "[Determination of the serum enzyme and dehydrogenase activity of circulating lymphocytes during hemosorption in dietary hypercholesterolemia]."
12/01/2013 - "Statins, also known as HMGCoA reductase inhibitors, are frequently used for the treatment of hypercholesterolemia and for the prevention of morbidity and mortality associated with cardiovascular disease. "
06/01/2001 - "These findings demonstrate that repeated CPA treatment on a 6 day schedule can be highly effective when combined with P450/P450 reductase gene therapy and suggest that repeated transduction of tumors with prodrug-activation genes may be necessary to achieve tumor eradication and a sustained therapeutic response."
06/01/2001 - "The same CPA schedule was much less effective in inducing regression of 9L tumors that were not transduced with P450/P450 reductase. "
01/01/1996 - "Assessment of HMGCoA reductase in liver and tumor indicated that these agents were effective in reaching these target sites. "
01/01/2015 - "Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models."
12/01/2009 - "In the current study, using radiolabeled ((14)C) 3BrPA in multiple cancer cell lines, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was identified as the primary intracellular target of 3BrPA, based on two-dimensional (2D) gel electrophoretic autoradiography, mass spectrometry and immunoprecipitation. "
03/01/2007 - "Taken together, these results suggest that AC will be a new potential natural product for the treatment of hyperlipidemia that exerts its actions through mechanisms of inhibiting HMGCoA reductase and activating LPL activities. "
10/01/2004 - "The remarkable anti-atherosclerotic effects of 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor have not been demonstrated in diet induced severe hyperlipidemia in rabbit model. "
01/01/2002 - "The great importance of HMGCoA reductase inhibitors (statins) in treatment of hyperlipidemia is well known, and accepted. "
12/01/1994 - "A principle of the treatment of hyperlipidemia, including secondary one associated with diabetes mellitus and renal disease, by HMGCoA reductase is discussed in this review."
11/01/2003 - "LCPUFAs are useful in the management of hyperlipidemia, inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, and may mediate the beneficial actions of statins. "
06/23/1997 - "Analysis of combined data from primary and secondary prevention trials showed a highly statistically significant reduction of stroke associated with the use of reductase inhibitor monotherapy (27% reduction in stroke; P = .001). "
03/01/2001 - "Ten homogenization strokes improved activity specific to reductase activity. "
05/01/2006 - "To study the relationship between methylenetrahydrofolate reductase (MTHFR) gene and ischemic stroke. "
12/01/2005 - "The aim of this study was to test whether the levels of these 2 markers and of acetylpolyamine oxidase (AcPAO) were increased in the plasma of stroke patients. "
01/15/1998 - "This meta-analysis of randomized, controlled trials suggests that in hyperlipidemic patients who have not previously had stroke, HMGcoA reductase inhibitors reduce the incidence of stroke."
|1.||Coenzyme A (CoA)
|2.||3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
|7.||Pyruvic Acid (Pyruvate)
|9.||glutaryl-coenzyme A (glutaryl-CoA)
|1.||Drug Therapy (Chemotherapy)
|4.||Renal Dialysis (Hemodialysis)